RxDoctor Payments Data

Margot Antonello

Family · Wynnewood, PANPI 1720657182

Payments from drug & device makers

$1,312in general payments, 2019–2025

Across 62 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$356
  • Lilly USA, LLC$178
  • Medtronic$167
  • Amgen$109
  • AbbVie$107
  • Tandem Diabetes Care, Inc.$106
  • plus $287 from 6 others

What the payments were for

  • Food & beverage$1,312100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,312 in reported general payments places this provider in the 75th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$41,392
Medicare patients
206
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide248$404,390
MounjaroTirzepatide186$257,832
JardianceEmpagliflozin116$147,530
TrulicityDulaglutide51$81,208
Tresiba Flextouch U-200Insulin Degludec36$37,835
Fiasp FlextouchInsulin Aspart (Niacinamide)21$32,526
Tresiba Flextouch U-100Insulin Degludec36$32,463
FarxigaDapagliflozin Propanediol22$27,396
Novolog FlexpenInsulin Aspart76$22,846
JanuviaSitagliptin Phosphate18$22,248
RybelsusSemaglutide20$19,825
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/713$18,423
InvokanaCanagliflozin17$15,083
Lantus SolostarInsulin Glargine,hum.Rec.Anlog127$13,280
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$12,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$356$424,215268 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$178$345,804260 claims
Boehringer IngelheimJardiance$60$147,530116 claims
AbbVieSynthroid$107$3,75034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,717 family providers in Pennsylvania.

Other family in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →